|
DGAP-News: SHOP APOTHEKE EUROPE N.V.
/ Key word(s): Development of Sales/Preliminary Results
NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA AND JAPAN OR ANY JURISDICTION IN WHICH OFFERS OR SALES OF THE SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW. SHOP APOTHEKE EUROPE continues its fast growth: Q4 sales up 38%, full year 2020 growth 38.1%.
In the DACH Segment (Germany, Austria, Switzerland), SHOP APOTHEKE EUROPE recorded 33.7% growth in Q4, resulting in sales of EUR 263.9 million. In the full year 2020, sales grew by 32.5% to EUR 815.5 million. In the International Segment (France, Belgium, Italy and the Netherlands), SHOP APOTHEKE EUROPE increased its sales by 68.2% to EUR 41.0 million in Q4 and by 78.3% to EUR 152.6 million in the full year. The sale of prescription drugs (Rx) increased by 17.6 % year-on-year, from EUR 186.5 million in 2019 to EUR 219.3 million in 2020. CFO Jasper Eenhorst comments: "We were able to raise our sales growth guidance three times last year because we seized the opportunities we saw and were quick to make the right decisions. This took us close to the billion-euro mark in sales in 2020. With the ongoing move to our new logistics centre and our fast-growing base of active, happy, customers we are also well positioned for continued growth in 2021." All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE will publish the complete annual report for the 2020 financial year on 3 March 2021. ABOUT SHOP APOTHEKE EUROPE.
Financial media: Investor relations: Thomas Schnorrenberg This publication constitutes an advertisement. This announcement does not constitute an offer for sale or a solicitation of an offer to purchase securities of SHOP APOTHEKE EUROPE N.V. in any jurisdiction. It does not constitute a securities prospectus. A public offer of securities of SHOP APOTHEKE EUROPE N.V. is not taking place. Statements contained herein could constitute so-called 'forward-looking statements'. Forward-looking statements can be recognized by words such as 'might,' 'will,' 'should,' 'plans,' 'anticipates,' 'anticipates,' 'estimates,' 'believes,' 'intends,' 'aims,' 'aim' or their negative form or corresponding modifications and comparable terms. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, levels of utilization, developments and achievements of the group or industry in which it operates to be materially different than those contained herein or implied. There should be no undue reliance on forward-looking statements. The group will not update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.
11.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | SHOP APOTHEKE EUROPE N.V. |
| Dirk Hartogweg 14 | |
| 5928 LV Venlo | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | |
| Internet: | -apotheke-europe.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y07 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1159557 |
| End of News | DGAP News Service |
|
|
1159557 11.01.2021
